I will take JNJ's estimate of on market by end of 2017
Ford is building a plant in Mexico and even if Trump was President he could do Nada to stop it. wegbox and you do not back the first ever Jewish man running for President. A historic moment and no one talks about it.
Clinical Trials dot gov the trial ends with final collection 2 months prior to date I gave and with small numbers in the trial data should release in 2 months after trial final data collection.
2010 Shareholder meeting at the old Lab now AST Dr Kelsey had mentioned that some do read but none would dare post the termination issue and SEC disclosure compliance.
It all depends on how long it takes JNJ to reach the 2 arm patient numbers and how long it takes them to analyze the numbers then shift to a single arm trial. My guess is by June but the latest would be Ash. We may get a shift from Phase 2 to Phase 3 and an opt in by JNJ first. By the way one would expect about 30% to 40% drop out rate on the MF trial using Scarlett's 66% stable disease figures from Dr Tefferi's trial data.
I wanted to thank you for the updates on the MF support group postings you have been doing very good parsing of information and questioning. From the answers and responses to your questioning there are several things that are evident. First the person posting to the board is an RN working at an NY surgical clinic and as a home health care nurse, and from her most recent post asking about side effects to Jakafi it makes me wonder if her mom was ever on Jakafi before. The fact that this is most likely a New York patient and New York came on line in mid October for recruiting and screening takes about 1 to 2 months makes me wonder if the 4 doses is accurate.
my only concern from reading the post is the daughter is a nurse yet her mom was never on Jakafi until you pointed out it was a requirement of entering the trial to have failed on Jakafi. My brothers wife is a now retired nurse and she knows all 16 meds my mom takes. Nurses tend to keep track of what their loved ones are taking in treatments.
The telomerase inhibitor imetelstat alone, and in combination with trastuzumab, decreases the cancer stem cell population and self-renewal of HER2+ breast cancer cells.
Koziel JE1, Herbert BS.
Cancer stem cells (CSCs) are thought to be responsible for tumor progression, metastasis, and recurrence. HER2 overexpression is associated with increased CSCs, which may explain the aggressive phenotype and increased likelihood of recurrence for HER2(+) breast cancers. Telomerase is reactivated in tumor cells, including CSCs, but has limited activity in normal tissues, providing potential for telomerase inhibition in anti-cancer therapy. The purpose of this study was to investigate the effects of a telomerase antagonistic oligonucleotide, imetelstat (GRN163L), on CSC and non-CSC populations of HER2(+) breast cancer cell lines. The effects of imetelstat on CSC populations of HER2(+) breast cancer cells were measured by ALDH activity and CD44/24 expression by flow cytometry as well as mammosphere assays for functionality. Combination studies in vitro and in vivo were utilized to test for synergism between imetelstat and trastuzumab. Imetelstat inhibited telomerase activity in both subpopulations. Moreover, imetelstat alone and in combination with trastuzumab reduced the CSC fraction and inhibited CSC functional ability, as shown by decreased mammosphere counts and invasive potential. Tumor growth rate was slower in combination-treated mice compared to either drug alone. Additionally, there was a trend toward decreased CSC marker expression in imetelstat-treated xenograft cells compared to vehicle control. Furthermore, the observed decrease in CSC marker expression occurred prior to and after telomere shortening, suggesting that imetelstat acts on the CSC subpopulation in telomere length-dependent and -independent mechanisms. Our study suggests addition of imetelstat to trastuzumab may enhance the effects of HER2 inhibition therapy, especially in the CSC population.
St. Louis, Missouri, United States
Baltimore, Maryland, United States
Bethesda, Maryland, United States
Louisville, Kentucky, United States
MF sites in US recruiting
Site #60521 Baltimore MD 21229-5201
Site #60568 Duarte CA 91010 369
Site #60565 La Jolla CA 92093 464
Site #60547 Seattle WA 98109 618
Site #60571 Rochester MN 55902 1534
Site #60537 St. Louis MO 63110 1671
Site #60538 Louisville KY 40202 1915
Site #61772 Greenville SC 29607 2158
Site #60536 Baltimore MD 21201 2378
Site #60566 Philadelphia PA 19104 2443
Site #60528 New York NY 10029 2491
Site #60532 Bronx NY 10467 2495
MDS sites in the US recruiting
Site #71197 Baltimore MD 21229-5201
Site #71232 St. Louis MO 63110 1671
Site #71224 Louisville KY 40207 1915
Site #71195 Bethesda MD 20817 2357
but growing at the same amount means the growth rate decreases because the base is higher. here is the example if China grows 7.1 every year for 3 years here is what happens to the growth rate. year 1 the growth rate is 7.1/100 = 7.1% year 2 it is 7.1/107.1= 6.6% year 3 is 7.1/113.7=6.24%.
NASDAQ Institutional ownership
Institutional Holdings 45.15%
Total Number of Holders 147
Total Shares Held 71,434,048
Total Value of Holdings $238,589,720
Net Activity (680,869)
calculated change in percentage of ownership 0.945% that is slightly less than a 1% change in amount owned by institutions. There were 22 that sold out and 14 New positions established. Some increased positions while others decreased.
Yahoo is always way off on the numbers